CRMD
Price
$12.50
Change
-$2.46 (-16.44%)
Updated
Jun 27 closing price
Capitalization
847.81M
38 days until earnings call
HOTH
Price
$1.13
Change
-$0.04 (-3.42%)
Updated
Jun 27 closing price
Capitalization
14.93M
Interact to see
Advertisement

CRMD vs HOTH

Header iconCRMD vs HOTH Comparison
Open Charts CRMD vs HOTHBanner chart's image
CorMedix
Price$12.50
Change-$2.46 (-16.44%)
Volume$9.9M
Capitalization847.81M
Hoth Therapeutics
Price$1.13
Change-$0.04 (-3.42%)
Volume$432.11K
Capitalization14.93M
CRMD vs HOTH Comparison Chart in %
Loading...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HOTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRMD vs. HOTH commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a Buy and HOTH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CRMD: $12.50 vs. HOTH: $1.13)
Brand notoriety: CRMD and HOTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRMD: 475% vs. HOTH: 31%
Market capitalization -- CRMD: $847.81M vs. HOTH: $14.93M
CRMD [@Biotechnology] is valued at $847.81M. HOTH’s [@Biotechnology] market capitalization is $14.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRMD’s FA Score shows that 0 FA rating(s) are green whileHOTH’s FA Score has 1 green FA rating(s).

  • CRMD’s FA Score: 0 green, 5 red.
  • HOTH’s FA Score: 1 green, 4 red.
According to our system of comparison, CRMD is a better buy in the long-term than HOTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 4 TA indicator(s) are bullish while HOTH’s TA Score has 5 bullish TA indicator(s).

  • CRMD’s TA Score: 4 bullish, 4 bearish.
  • HOTH’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CRMD and HOTH are a good buy in the short-term.

Price Growth

CRMD (@Biotechnology) experienced а -8.16% price change this week, while HOTH (@Biotechnology) price change was -6.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.95%, and the average quarterly price growth was +6.81%.

Reported Earning Dates

CRMD is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRMD($848M) has a higher market cap than HOTH($14.9M). CRMD YTD gains are higher at: 54.321 vs. HOTH (51.049). CRMD has higher annual earnings (EBITDA): 17.7M vs. HOTH (-9.53M). CRMD has more cash in the bank: 77.5M vs. HOTH (11.3M). HOTH has less debt than CRMD: HOTH (28.9K) vs CRMD (477K). CRMD has higher revenues than HOTH: CRMD (82.6M) vs HOTH (0).
CRMDHOTHCRMD / HOTH
Capitalization848M14.9M5,691%
EBITDA17.7M-9.53M-186%
Gain YTD54.32151.049106%
P/E Ratio50.00N/A-
Revenue82.6M0-
Total Cash77.5M11.3M686%
Total Debt477K28.9K1,651%
FUNDAMENTALS RATINGS
CRMD vs HOTH: Fundamental Ratings
CRMD
HOTH
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
60100
SMR RATING
1..100
4698
PRICE GROWTH RATING
1..100
3638
P/E GROWTH RATING
1..100
45100
SEASONALITY SCORE
1..100
n/a1

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HOTH's Valuation (21) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRMD (77) in the Medical Specialties industry. This means that HOTH’s stock grew somewhat faster than CRMD’s over the last 12 months.

CRMD's Profit vs Risk Rating (60) in the Medical Specialties industry is somewhat better than the same rating for HOTH (100) in the Pharmaceuticals Major industry. This means that CRMD’s stock grew somewhat faster than HOTH’s over the last 12 months.

CRMD's SMR Rating (46) in the Medical Specialties industry is somewhat better than the same rating for HOTH (98) in the Pharmaceuticals Major industry. This means that CRMD’s stock grew somewhat faster than HOTH’s over the last 12 months.

CRMD's Price Growth Rating (36) in the Medical Specialties industry is in the same range as HOTH (38) in the Pharmaceuticals Major industry. This means that CRMD’s stock grew similarly to HOTH’s over the last 12 months.

CRMD's P/E Growth Rating (45) in the Medical Specialties industry is somewhat better than the same rating for HOTH (100) in the Pharmaceuticals Major industry. This means that CRMD’s stock grew somewhat faster than HOTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRMDHOTH
RSI
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 21 days ago
82%
Bullish Trend 19 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
76%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HOTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADGCX16.150.11
+0.69%
AB Core Opportunities C
MXVHX6.920.03
+0.44%
Empower Large Cap Value Instl
PURYX56.110.24
+0.43%
Putnam Research Y
FRURX23.870.05
+0.21%
Franklin Utilities R
HUDIX24.25-0.02
-0.08%
Huber Large Cap Value Inv

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
-16.44%
MURA - CRMD
39%
Loosely correlated
N/A
FULC - CRMD
30%
Poorly correlated
-3.79%
BTAI - CRMD
30%
Poorly correlated
-12.81%
OVID - CRMD
29%
Poorly correlated
-11.95%
HRMY - CRMD
27%
Poorly correlated
+0.38%
More

HOTH and

Correlation & Price change

A.I.dvisor tells us that HOTH and PPTDF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HOTH and PPTDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HOTH
1D Price
Change %
HOTH100%
-3.42%
PPTDF - HOTH
28%
Poorly correlated
N/A
CRNX - HOTH
28%
Poorly correlated
-0.10%
INO - HOTH
28%
Poorly correlated
-6.22%
NRXP - HOTH
27%
Poorly correlated
-2.29%
CRMD - HOTH
26%
Poorly correlated
-16.44%
More